Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phenoxodiol in Castrate and Non-Castrate Prostate Cancer
NCT00557037Phase 2Completed
- Sponsor
- MEI Pharma
- Start
- Nov 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of idronoxil in prostate cancer (PCa) (2 arms), sponsored by MEI Pharma. Primary endpoint: Proportion of patients with 50% post-therapy PSA decline at 12 weeks. Started Nov 2007; status: completed.
02
Drugs
idronoxil
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00557037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00557037.